Capítulo 1772: Chapter 1257: From Zero to One
“It proves that our path is correct. This is not from sheer luck, but an inevitable result of our autonomous research ecosystem’s logical reasoning and iterative optimization—this is the success of our thodology!”
His gaze swept across each excited face: “However, this is just the beginning. The X-2 molecule still needs to undergo the test of preclinical animal experints, and ultimately, it must prove its safety and efficacy in human clinical trials. The system we’ve built also needs to address more complex issues in the broader biopharmaceutical field.”
“We have proven that this road is viable, and next, we need to broaden this road into a grand avenue leading to the future!”
Yang Ping’s words were like a shot of adrenaline, swiftly transforming everyone’s joy into a firr belief and motivation to move forward.
“He Zijian, imdiately organize all in vitro data for the X-2 molecule and prepare the preliminary information for the IND (Investigational New Drug) application.”
“Wang Chao, continue to optimize the sensors, iterating toward making them more portable and high-throughput. We need to make it a standard configuration of the platform and hand over the data to Ruixing dical for the developnt of such comrcial equipnt.”
“Chu Xiaoxiao, finalize the AI model, but summarize the training experience to form a standardized operating procedure (SOP) to prepare for the next target.”
“Liu Yang, initiate the process scale-up study for the X-2 molecule, aiming to et the sample requirents for clinical phase one trials.”
“Jiang Jitong, imdiately liaise with the Animal Experint Center to start the preclinical safety and efficacy evaluation for the X-2 molecule!”
The instructions were clear and straightforward, and the entire team began operating at high speed again like a finely tuned gear.
In the following days, the Laboratory’s focus shifted to preparing for “X-2” entering preclinical research. The organization of data, writing of materials, communication with partners… each task was tedious yet ticulous, but the team’s morale was high and their efficiency astounding.
Six individuals propelled this enormous experint forward, benefiting from a new path and the participation of Nandu dical University’s AI.
anwhile, Yang Ping, in the System Space, launched new experints: based on the successful experience and data from ‘X-2,’ optimizing the platform and expanding targets to fields like tumor immunotherapy (such as PD-1/PD-L1 inhibitor enhancent) and autoimmune diseases, to find new candidate molecules.
In the real world, the animal experint for “X-2” comnced on schedule. From mice to rats, and then to non-human primates, initial reports kept coming back:
“‘X-2′ shows a very strong adjuvant effect in mouse models, significantly enhancing vaccine immunogenicity!”
“No significant abnormalities were observed in long-term toxicity tests!”
“In primates, it shows clear advantages compared to existing adjuvants!”
Each piece of good news was like a solid step paving the road for “X-2” to reach clinical applications.
One afternoon, Jiang Jitong knocked on Yang Ping’s office door with a serious expression.
“Professor Yang, so rumors have been received.” Jiang Jitong placed a brief report on Yang Ping’s desk, “Internationally, so scholars at academic circles and industry conferences have begun questioning the controllability and reliability of biologics developed entirely outside their technical platforms. Also, there are signs they might target us in terms of intellectual property.”
Yang Ping picked up the report and quickly browsed through it, his face showing no surprise.
“The tree wishes to remain quiet, but the wind will not subside. This is inevitable.” He set down the report, “We’ve forged a new path and touched others’ interests; they cannot remain indifferent. Alongside technical blockades, they’ll use public opinion and rules to suppress us—this is a massive system; it’s sothing we’ve expected.”
“So what do we…” Jiang Jitong expressed so concern.
“No need to be tense.” Yang Ping turned around, his gaze sharp yet steady, “First, all of ‘X-2’s design and data originate from our autonomous platform; the intellectual property is clear and can withstand scrutiny. They probably still can’t grasp our technical details. Second, our true confidence cos from data and efficacy; ‘X-2’s animal experint data is our moat. Third, and most importantly…”
He paused, his tone carrying an indisputable strength: “We are not fighting alone. The Ruixing Alliance aggregates not just technology and talent but also the top dostic resources in regulation, intellectual property, and clinical practice. They will help us resolve these issues, so we shouldn’t worry about these matters and should focus all our attention on the experints, understand?”
Jiang Jitong nodded, feeling that Professor Yang made sense, and everyone should hold their positions and do what they are good at.
Yang Ping imdiately communicated with Huang Jiacai. Huang Jiacai was already aware of this information and had convened an ergency eting with the main heads of the alliance. During the eting, he did not hide the potential challenges faced but viewed it as an opportunity to subject the autonomous system to a more rigorous test.
“This is a battle we must win.” Huang Jiacai said at the end of the eting, “This is not just about the fate of the ‘X-2’ product but whether our new path can be recognized and stand tall. We must et any challenge with the most rigorous data, the most transparent processes, and the first attitude.”
He deployed counterasures: by the alliance’s intellectual property expert team, conducting a comprehensive FTO (freedom to operate) analysis on ‘X-2’ and related platform technologies, building a strong patent barrier; by the regulatory affairs team, communicate in advance with the national drug administration and other departnts, demonstrating the scientific and reliable nature of the independent research and developnt path; by the public relations team, prepare necessary materials to convey the correct ssage to the outside world at the right ti.
True innovation has never been smooth sailing. It requires breaking through technical barriers and dismantling the constraints of thoughts and the encirclent of existing interest structures.
“X-2” is a seed, and the autonomous research and developnt ecosystem is the soil nurturing the seed. Now, the seed has broken through the soil, showing strong vitality. Next, it must endure the baptism of wind and rain to grow into a towering tree.
Yang Ping also continued his progress steadily, instructing He Zijian: “Zijian, prepare a detailed phase report of the ‘X-2’ project, especially the complete logic and data chains of the platform’s autonomous design and iterative optimization. We need to let everyone see that this is not a coincidence; it is a scientific inevitability.”
As night deepened, the lights in Yang Ping’s office still shone. He was drafting a more extensive proposal, envisioning the establishnt of an open, collaborative, and self-evolving “China Biopharmaceutical Innovation Factory” based on existing successful experiences. This factory would not only serve his own Laboratory but also provide tools, algorithms, computing power, and thodological support to all dostic research teams and biotechnology companies committed to original innovation.
Yang Ping is not content with the success of one or two projects or the developnt of one or two new drugs; he aims to fundantally transform China’s biopharmaceutical industry’s innovation ecosystem, creating a vibrant innovation source independent of any external resources.
Outside the window, the stars twinkled, mirroring the lights in the laboratory and offices.
User Comments
0 comments from readers